Imunon, Inc. Common Stock
$1.36
-$0.02 (-1.45%)
$1.33Day Range$1.42
Key Statistics
Market Cap
$7.74M
Shares Outstanding
5.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 24, 1995
Round Lot
100
Locale
US
Trading Data
Day Open
$1.40
Day High
$1.42
Day Low
$1.33
Volume
62.8K
VWAP
$1.38
Prev Close
$1.38
Transactions
--
Acc. Volume
--
About Imunon, Inc. Common Stock
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
PHARMACEUTICAL PREPARATIONSSIC 283420 employees997 LENOX DRIVE, LAWRENCEVILLE, NJ, 08648(609) 896-9100IPO Jul 24, 1995US / STOCKSActiveWebsite
Identifiers
- CIK
- 0000749647
- Composite FIGI
- BBG000BJJGT8
- Share Class FIGI
- BBG001S6FLZ2
- Ticker Root
- IMNN
- SIC Code
- 2834
About Imunon, Inc. Common Stock (IMNN) Stock
Imunon, Inc. Common Stock (IMNN) closed the 2026-09-18 session at $1.36, down 1.45% versus the previous close (-0.02). The stock opened at $1.40 and traded between $1.33 and $1.42 during that session. Session trading volume was 63K shares. The volume-weighted average price (VWAP) is $1.38.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
Imunon, Inc. Common Stock has a market capitalization of $7.7 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. IMNN is listed on the XNAS exchange. The company employs approximately 20 people. Imunon, Inc. Common Stock is headquartered in LAWRENCEVILLE, NJ. The recorded listing date is 1995-07-24.
On this page you can find market IMNN stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.